By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen said today that it has obtained a non-exclusive license from Johns Hopkins University to incorporate a BRAF mutation sequence into its molecular diagnostic products.

Terms of the licensing deal includes the use of the mutation, BRAF V600E, as a component in diagnostic test kits and use of it in Asuragen's CLIA laboratory for clinical research and patient testing. Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.